Plain-English translation of NCT03829254 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see how safe it is and whether it helps people with advanced cancers (solid tumors and lymphoma). The study has two main parts: first, researchers will test different doses to find the safest amount, then they'll test that dose in a larger group of patients to see if the medication actually works against cancer.
Current cancer treatments don't work for everyone, and some people's cancers stop responding to available options. This trial is exploring whether this new medication could offer another option for people with advanced cancer who have limited other choices.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an infusion into your vein either once a week or once every two weeks, depending on which group you're in. Some participants may also receive another immunotherapy drug () alongside the new medication. You'll have regular clinic visits for blood tests, scans, and check-ups to monitor your health and how your cancer is responding, and you may be asked to provide tumor biopsies (small tissue samples) so researchers can study how the medication affects your cancer cells.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United Kingdom